新冠疫情期间的重症监护
Intensive Care during the COVID-19 Pandemic.
作者信息
Wang Ying, Jin Yuefei, Yang Haiyan
机构信息
Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China.
出版信息
Vaccines (Basel). 2023 Jan 4;11(1):125. doi: 10.3390/vaccines11010125.
Abstract
The novel coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a sudden sharp rise in hospitalizations for pneumonia with multiorgan disease [...].
摘要
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019年新型冠状病毒病（COVID-19）大流行，导致肺炎合并多器官疾病的住院人数突然急剧上升[……]
相似文献
1
Intensive Care during the COVID-19 Pandemic.
Vaccines (Basel). 2023 Jan 4;11(1):125. doi: 10.3390/vaccines11010125.
2
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.
JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
3
Human and novel coronavirus infections in children: a review.
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
4
Severe Acute Respiratory Syndrome by SARS-CoV-2 Infection or Other Etiologic Agents Among Brazilian Indigenous Population: An Observational Study from the First Year of Coronavirus Disease (COVID)-19 Pandemic.
Lancet Reg Health Am. 2022 Apr;8:100177. doi: 10.1016/j.lana.2021.100177. Epub 2022 Jan 7.
5
Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy.
Am J Emerg Med. 2021 Jul;45:156-161. doi: 10.1016/j.ajem.2020.08.005. Epub 2020 Aug 16.
6
The novel zoonotic COVID-19 pandemic: An expected global health concern.
J Infect Dev Ctries. 2020 Mar 31;14(3):254-264. doi: 10.3855/jidc.12671.
7
[The first wave of COVID-19 in Intensive care].
Rev Med Liege. 2020;75(S1):18-28.
8
[Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):571-592. doi: 10.13345/j.cjb.200115.
9
Remdesivir against COVID-19 and Other Viral Diseases.
Clin Microbiol Rev. 2020 Oct 14;34(1). doi: 10.1128/CMR.00162-20. Print 2020 Dec 16.
10
Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019: A Clinical Overview and Primer.
Biopreserv Biobank. 2020 Dec;18(6):492-502. doi: 10.1089/bio.2020.0066. Epub 2020 Jul 23.
引用本文的文献
1
COVID-19: association of the National Early Warning Score with triage categories, severity and outcomes.
Rev Bras Enferm. 2025 Aug 8;78(3):e20240069. doi: 10.1590/0034-7167-2024-0069. eCollection 2025.
2
Higher Serum Monolaurin Is Associated with a Lower Risk of COVID-19: Results from a Prospective Observational Cohort Study.
Int J Mol Sci. 2025 Mar 10;26(6):2452. doi: 10.3390/ijms26062452.
3
A Meta-Analysis on the Association between Peptic Ulcer Disease and COVID-19 Severity.
Vaccines (Basel). 2023 Jun 11;11(6):1087. doi: 10.3390/vaccines11061087.
本文引用的文献
1
Prone Positioning: A Safe and Effective Procedure in Pregnant Women Presenting with Severe Acute Respiratory Distress Syndrome.
Vaccines (Basel). 2022 Dec 19;10(12):2182. doi: 10.3390/vaccines10122182.
2
Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression.
Vaccines (Basel). 2022 Dec 19;10(12):2180. doi: 10.3390/vaccines10122180.
3
Antibiotics Usage and Resistance among Patients with Severe Acute Respiratory Syndrome Coronavirus 2 in the Intensive Care Unit in Makkah, Saudi Arabia.
Vaccines (Basel). 2022 Dec 14;10(12):2148. doi: 10.3390/vaccines10122148.
4
Neutralizing Antibody Responses Elicited by Inactivated Whole Virus and Genetic Vaccines against Dominant SARS-CoV-2 Variants during the Four Epidemic Peaks of COVID-19 in Colombia.
Vaccines (Basel). 2022 Dec 14;10(12):2144. doi: 10.3390/vaccines10122144.
5
Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CorV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants.
Vaccines (Basel). 2022 Dec 9;10(12):2110. doi: 10.3390/vaccines10122110.
6
Preclinical Toxicity and Immunogenicity of a COVID-19 Vaccine (ZF2001) in Cynomolgus Monkeys.
Vaccines (Basel). 2022 Dec 5;10(12):2080. doi: 10.3390/vaccines10122080.
7
Predicted Impacts of Booster, Immunity Decline, Vaccination Strategies, and Non-Pharmaceutical Interventions on COVID-19 Outcomes in France.
Vaccines (Basel). 2022 Nov 28;10(12):2033. doi: 10.3390/vaccines10122033.
8
Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2.
Vaccines (Basel). 2022 Nov 24;10(12):1997. doi: 10.3390/vaccines10121997.
9
Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine.
Vaccines (Basel). 2022 Nov 17;10(11):1948. doi: 10.3390/vaccines10111948.
10
Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial.
Vaccines (Basel). 2022 Nov 4;10(11):1865. doi: 10.3390/vaccines10111865.
Zotero 插件